RNA Polymerase I: A novel target in the treatment of MYC driven malignancies

RNA 聚合酶 I：治疗 MYC 驱动的恶性肿瘤的新靶点

• 批准号: nhmrc : 1003270
• 负责人: Prof Grant Mcarthur
• 金额: $ 40.41万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/rna-polymerase-i-driven-malignancies/108911
• 关键词: RNA; Polymerase; novel; target; treatment

Synthesis of ribosomes, the cellular protein synthetic machinery, is dysregulated during cancer leading to the hypothesis that it may be causative in the malignant process. This application will test this hypothesis using novel inhibitors or ribosome biogenesis in a mouse genetic model termed E�-MYC that faithfully that replicates human B-cell lymphoma. These studies will uncover novel mechanisms in malignant transformation and identify new therapeutics in the treatment of human cancer.

核糖体的合成（细胞蛋白质合成机制）在癌症过程中失调，导致人们假设它可能是恶性过程的原因。该应用将在名为 E�-MYC 的小鼠遗传模型中使用新型抑制剂或核糖体生物发生来测试这一假设，该模型忠实地复制了人类 B 细胞淋巴瘤。这些研究将揭示恶性转化的新机制，并确定治疗人类癌症的新疗法。